| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
|
Purity: ≥98%
Ofloxacin (Hoe-280; DL8280; DL-8280, DR-3355, Hoe280, ORF-28489, Ru-43280) is a synthetic, orally bioavailable and broad-spectrum antibiotic of the fluorinated quinolone class used for the treatment of a variety of bacterial infections such as pneumonia, cellulitis, UTIs-urinary tract infections, prostatitis, and plague. Ofloxacin acts by inhibiting DNA gyrase.
| Targets |
Topo II; Topoisomerase IV
|
|---|---|
| ln Vitro |
Ofloxacin (Hoe-280) is a fluoroquinolone that works primarily by inhibiting the bacterial enzyme known as DNA gyrase. While it is not as effective against anaerobes, it exhibits a wide range of activity in vitro against aerobic Gram-negative and Gram-positive bacteria[1]. Like other 4-quinolones, ofloxacin (Hoe-280) is unique among first-line medications for treating bacterial infections because it affects the synthesis of bacterial DNA rather than cell walls or proteins[2].
|
| ln Vivo |
Ofloxacin (Hoe-280) (20 mg/kg), norfloxacin (40 mg/kg), pefloxacin mesylate dihydrate (40 mg/kg) and ciprofloxacin (50 mg/kg) are administered by gavage twice daily for three consecutive weeks. Six weeks following therapy, the test animals are put to sleep, and samples of the Achilles tendon are taken. Biomechanical testing was conducted using a computer-monitored tensile testing apparatus. The control group's mean elastic modulus was notably higher than the norfloxacin and pefloxacin groups' (p<0.05 and p<0.01, respectively). The control group exhibited a significantly higher mean yield force (YF) compared to the groups treated with ciprofloxacin, norfloxacin, and pefloxacin (p<0.001, p<0.05, and p<0.01, respectively). Compared to the ciprofloxacin, norfloxacin, and pefloxacin groups, the control group's mean ultimate tensile force (UTF) was significantly higher (p<0.001, p<0.05, and p<0.01, respectively). In the tendons of the ciprofloxacin, pefloxacin, and ofloxacin treated groups, hyaline degeneration and fiber disarray were noted, but only in the ciprofloxacin and pefloxacin groups was myxomatous degeneration[3].
|
| References |
| Molecular Formula |
C18H20FN3O4
|
|
|---|---|---|
| Molecular Weight |
361.37
|
|
| Exact Mass |
361.14
|
|
| Elemental Analysis |
C, 59.83; H, 5.58; F, 5.26; N, 11.63; O, 17.71
|
|
| CAS # |
82419-36-1
|
|
| Related CAS # |
|
|
| Appearance |
Off-white to light yellow crystalline powder
|
|
| SMILES |
CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
|
|
| InChi Key |
GSDSWSVVBLHKDQ-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)
|
|
| Chemical Name |
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7672 mL | 13.8362 mL | 27.6725 mL | |
| 5 mM | 0.5534 mL | 2.7672 mL | 5.5345 mL | |
| 10 mM | 0.2767 mL | 1.3836 mL | 2.7672 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04496024 | Recruiting | Drug: ofloxacin Other: questionnaire |
Ofloxacin Bone and Joint Infection |
Centre Hospitalier Universitaire, Amiens |
June 2, 2020 | Not Applicable |
| NCT03655665 | Recruiting | Drug: Ofloxacin otic solution | Otitis Media | Boston Children's Hospital | May 16, 2019 | Phase 4 |
| NCT03933631 | Recruiting | Drug: Ofloxacin Drug: Prednisolone |
Glaucoma | Montefiore Medical Center | May 1, 2019 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA